KIORA PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: March 25, 2026 | By: | /s/ Brian M. Strem |
|---|---|---|
| President and Chief Executive Officer | ||
| Date: March 25, 2026 | By: | /s/ Melissa Tosca |
| Chief Financial Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Brian M. Strem | President and Chief Executive Officer | March 25, 2026 |
| Brian M. Strem | (Principal Executive Officer) | |
| /s/ Melissa Tosca | Chief Financial Officer | March 25, 2026 |
| Melissa Tosca | (Principal Financial and Accounting Officer) | |
| /s/ Praveen Tyle | Director | March 25, 2026 |
| Praveen Tyle | ||
| /s/ Lisa Walters-Hoffert | Director | March 25, 2026 |
| Lisa Walters-Hoffert | ||
| /s/ David Hollander | Director | March 25, 2026 |
| David Hollander | ||
| /s/ Aron Shapiro | Director | March 25, 2026 |
| Aron Shapiro | ||
| /s/ Erin Parsons | Director | March 25, 2026 |
| Erin Parsons | ||
| /s/ Carmine Stengone | Director | March 25, 2026 |
| Carmine Stengone | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.